GSE14580

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

24 case / 6 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response

Overall design

Twenty-four patients with active UC, refractory to corticosteroids and/or immunosuppression, underwent colonoscopy with biopsies from diseased colon within a week prior to the first intravenous infusion of 5 mg infliximab per kg body weight. Response to infliximab was defined as endoscopic and histologic healing at 4-6 weeks after first infliximab treatment. Six control patients with normal colonoscopy were included. Total RNA was isolated from colonic mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
30 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Curated expression experiment linkage and source URL.

Expression Atlas accession
E-GEOD-14580
Available
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

7 linked publications 7 DOIs

Primary publication

  1. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut, 2009

Related publications

  1. Management of ulcerative colitis by dichloroacetate: Impact on NFATC1/NLRP3/IL1B signaling based on bioinformatics analysis combined with in vivo experimental verification. Inflammopharmacology, 2024
  2. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis. Autoimmunity, 2022
  3. SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes. European journal of gastroenterology & hepatology, 2022
  4. Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy. BioMed research international, 2019
  5. Construction of a molecular inflammatory predictive model with histone modification-related genes and identification of CAMK2D as a potential response signature to infliximab in ulcerative colitis. Frontiers in immunology, 2023
  6. Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis. Life (Basel, Switzerland), 2023
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Ulcerative colitis 24 samples
  • Likely control group Control 6 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Interpreted disease metadata: Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: Expression Atlas curated experiment link is available.
  • External evidence: PubMed links 7 publications; 7 DOIs available: PMID 19700435, PMID 31886172, PMID 35102110, PMID 35876170, PMID 36983834.
  • Publication context: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.. Gut, 2009. PMID 19700435. DOI 10.1136/gut.2009.178665.
  • Publication context: Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy.. BioMed research international, 2019. PMID 31886172. DOI 10.1155/2019/1475705.
  • Publication context: SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.. European journal of gastroenterology & hepatology, 2022. PMID 35102110. DOI 10.1097/MEG.0000000000002349.
  • Publication context: 4 additional linked PubMed publications are available.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

148 fields

Sample Group Preview

30 rows shown
Show Hide
Study totals: Case 24 | Control 6 | Unassigned 0 | Excluded 0 | Ambiguous 0 30 rows shown
Group Role Accession Title Source / characteristics Reason
Ulcerative colitis Case GSM364633 UCR1_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364634 UCR2_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364635 UCR3_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364636 UCR4_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364637 UCR5_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364638 UCR6_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364639 UCR7_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364640 UCR8_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364641 UCNR1_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364642 UCNR2_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364643 UCNR3_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364644 UCNR4_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364645 UCNR5_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364646 UCNR6_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364647 UCNR7_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364648 UCNR8_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364649 UCNR9_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364650 UCNR10_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364651 UCNR11_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364652 UCNR12_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364653 UCNR13_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364654 UCNR14_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364655 UCNR15_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364656 UCNR16_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Control Control GSM364627 CO1 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364628 CO2 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364629 CO3 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364630 CO4 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364631 CO5 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364632 CO6 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.